Utrecht, the Netherlands – AQTIS Medical™ BV, announces that its bioresorbable dermal filler Ellansé™ has been awarded the prestigious Frost & Sullivan award 2011 in the category ‘Dermal Filler Innovation of the Year’.
AQTIS Medical™ proudly accepted this prestigious award as recognition of the innovative technology presented in this dermal filler. The Frost & Sullivan report highlights some of the unique features that Ellansé offers the aesthetics market, and benefits it will bring to both health care professionals and patients.
Some highlights of the Frost & Sullivan report on the Ellansé™ dermal filler Family:
“This novel range of dermal fillers supports safe and cost-effective treatments in aesthetic medicine and surgery, through immediate and sustained performance, tunable longevity and total bioresorbability (STAT Technology™). Aesthetic surgeons have observed positive results from the use of Ellansé™, recommending it for most cosmetic applications.”
Ellansé™ has been designed to suit a wide range of customer needs – based on the desired duration of action, clients can choose the appropriate Ellansé™ variant. This enables its use across a wide spectrum of treatment procedures.
Unlike hyaluronic acid (HA) fillers, Ellansé™ offers superior bioresorption, coupled with maximum safety. Moreover, it delivers results that last twice as long as other leading fillers due to the fact that Ellansé™ acts as a biostimulator, helping patients generate their own new collagen (neocollagenesis). Importantly, during the final stages of bioresorption, the PCL microparticles lose mass and are completely resorbed by intracellular phagocytosis and excreted readily through the metabolic pathway.
The Technology Innovation Award is presented to the company that has excelled in the following criteria: uniqueness of technology, impact on functionality, impact on customer value and relevance of innovation to industry.”